InsiderTrades.com logo

HCWB Insider Trading

Insider Ownership Percentage: 42.70%
Insider Buying (Last 12 Months): $305,032.00
Insider Selling (Last 12 Months): $0.00

HCW Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at HCW Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HCW Biologics Share Price & Price History

Current Price: $4.35
Price Change: ▼ Price Decrease of -0.07 (-1.58%)
As of 07/11/2025 05:00 PM ET

This chart shows the closing price history over time for HCWB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

HCW Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2025Gary M WinerDirectorBuy2,308$26.00$60,008.002,733View SEC Filing Icon  
5/8/2025Lee FlowersSVPBuy962$26.00$25,012.005,720View SEC Filing Icon  
5/8/2025Rebecca ByamCFOBuy8,462$26.00$220,012.0043,010View SEC Filing Icon  
9/14/2023Hing C WongCEOBuy45$83.20$3,744.00382,871View SEC Filing Icon  
9/13/2023Gary M WinerDirectorBuy13$82.00$1,066.00398View SEC Filing Icon  
9/13/2023Rebecca ByamCFOBuy125$84.00$10,500.0014,348View SEC Filing Icon  
9/11/2023Gary M WinerDirectorBuy2$82.00$164.00372View SEC Filing Icon  
9/11/2023Rebecca ByamCFOBuy125$82.00$10,250.0014,098View SEC Filing Icon  
9/8/2023Rebecca ByamCFOBuy125$80.80$10,100.0013,973View SEC Filing Icon  
9/7/2023Gary M WinerDirectorBuy1$78.00$78.00370View SEC Filing Icon  
9/6/2023Rebecca ByamCFOBuy125$78.00$9,750.0013,723View SEC Filing Icon  
9/5/2023Gary M WinerDirectorBuy10$70.00$700.00368View SEC Filing Icon  
6/9/2023Rebecca ByamCFOBuy500$82.40$41,200.0013,598View SEC Filing Icon  
6/8/2023Lee FlowersSVPBuy250$86.40$21,600.002,782View SEC Filing Icon  
6/7/2023Rebecca ByamCFOBuy500$81.20$40,600.0012,981View SEC Filing Icon  
6/5/2023Rebecca ByamCFOBuy500$66.80$33,400.0012,004View SEC Filing Icon  
6/1/2023Hing C WongCEOBuy20$64.80$1,296.00382,806View SEC Filing Icon  
5/30/2023Gary M WinerDirectorBuy21$60.80$1,276.80346View SEC Filing Icon  
5/30/2023Hing C WongCEOBuy75$62.00$4,650.00382,736View SEC Filing Icon  
5/26/2023Rebecca ByamCFOBuy500$66.40$33,200.0011,504View SEC Filing Icon  
5/24/2023Rebecca ByamCFOBuy500$64.40$32,200.0010,504View SEC Filing Icon  
5/22/2023Rebecca ByamCFOBuy836$61.20$51,163.209,878View SEC Filing Icon  
9/14/2022Rebecca ByamCFOBuy375$103.20$38,700.008,198View SEC Filing Icon  
9/12/2022Rebecca ByamCFOBuy375$106.00$39,750.007,448View SEC Filing Icon  
9/8/2022Hing C WongCEOBuy100$106.80$10,680.00382,511View SEC Filing Icon  
8/29/2022Rebecca ByamCFOBuy250$102.80$25,700.006,643View SEC Filing Icon  
8/26/2022Rebecca ByamCFOBuy250$101.60$25,400.006,393View SEC Filing Icon  
8/24/2022Rebecca ByamCFOBuy1,250$100.00$125,000.005,136View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for HCW Biologics (NASDAQ:HCWB)

2.96% of HCW Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HCW Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/2/2024Pullen Investment Management LLC85,116$0.15M0.1%N/A0.225%Search for SEC Filing on Google Icon
2/9/2024Avantax Planning Partners Inc.179,541$0.22M0.0%N/A0.499%Search for SEC Filing on Google Icon
2/9/2023HighTower Advisors LLC269,869$0.52M0.0%+19.6%0.752%Search for SEC Filing on Google Icon
11/15/2021HighTower Advisors LLC14,000$45K0.0%N/A0.039%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
HCW Biologics logo
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Read More on HCW Biologics

Today's Range

Now: $4.35
Low: $4.24
High: $4.42

50 Day Range

MA: $6.13
Low: $3.75
High: $10.05

52 Week Range

Now: $4.35
Low: $3.55
High: $100.80

Volume

37,284 shs

Average Volume

281,605 shs

Market Capitalization

$6.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Who are the company insiders with the largest holdings of HCW Biologics?

HCW Biologics' top insider investors include:
  1. Hing C Wong (CEO)
  2. Rebecca Byam (CFO)
  3. Lee Flowers (SVP)
  4. Gary M Winer (Director)
Learn More about top insider investors at HCW Biologics.